AI Portfolio Summary
In 2025 Q4, Cormorant Asset Management, LP maintained a portfolio of 42 distinct positions. The most significant new addition to the portfolio was INVESCO QQQ TR, which now represents 7.10% of the total fund value. Conversely, Cormorant Asset Management, LP completely exited their position in ARCELLX INC.
Total Positions
42
Quarter
2025 Q4
Top Holding
PRAX (12.9%)
Top 10 Concentration
69.4%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 42
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 12.95% | 3.66% |
#1
10
Prev: #11
|
6.5 | -50,000 | -5.0% |
P
S
|
950,000 | $280,003,000 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBOT
BRIDGEBIO ONCOL...
|
Healthcare | 10.35% | 14.29% |
#2
1
Prev: #1
|
6.5 | no change | no change |
P
S
|
17,878,594 | $223,839,997 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 8.42% | 11.42% |
#3
1
Prev: #2
|
4.4 | -600,000 | -30.8% |
P
S
|
1,350,000 | $182,054,250 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QQQ
PUT
INVESCO QQQ TR
|
PUT Option | 7.10% | — |
#4
Prev: #—
|
6.8 | 250,000 | no change |
NEW
|
250,000 | $153,577,500 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EYPT
EYEPOINT INC
|
Healthcare | 6.98% | 8.18% |
#5
2
Prev: #3
|
3.8 | -60,000 | -0.7% |
P
S
|
8,265,000 | $151,001,550 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IWM
PUT
ISHARES TR
|
PUT Option | 5.69% | — |
#6
Prev: #—
|
5.8 | 500,000 | no change |
NEW
|
500,000 | $123,080,000 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XBI
PUT
SPDR SERIES TRU...
|
PUT Option | 5.64% | — |
#7
Prev: #—
|
5.8 | 1,000,000 | no change |
NEW
|
1,000,000 | $121,930,000 | 2019 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPP
RAPPORT THERAPE...
|
Healthcare | 4.25% | 6.54% |
#8
4
Prev: #4
|
2.2 | -165,000 | -5.2% |
P
S
|
3,027,521 | $91,854,987 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 4.24% | 5.02% |
#9
4
Prev: #5
|
2.2 | -200,000 | -14.3% |
P
S
|
1,200,000 | $91,788,000 | 2019 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DRUG
BRIGHT MINDS BI...
|
Healthcare | 3.82% | 4.43% |
#10
3
Prev: #7
|
2.5 | no change | no change |
P
S
|
1,059,331 | $82,670,191 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 3.77% | 4.49% |
#11
5
Prev: #6
|
2.0 | -725,000 | -18.1% |
P
S
|
3,285,000 | $81,517,275 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OLMA
OLEMA PHARMACEU...
|
Healthcare | 3.18% | — |
#12
Prev: #—
|
4.8 | 2,750,000 | no change |
NEW
|
2,750,000 | $68,750,000 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 2.65% | 0.99% |
#13
12
Prev: #25
|
4.1 | 2,361,260 | 118.4% |
P
S
|
4,355,433 | $57,404,607 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INSM
INSMED INC
|
Healthcare | 2.21% | 4.27% |
#14
5
Prev: #9
|
0.9 | -155,000 | -36.0% |
P
S
|
275,000 | $47,861,000 | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENGN
ENGENE HOLDINGS...
|
Healthcare | 1.67% | 1.10% |
#15
8
Prev: #23
|
3.7 | 1,676,405 | 72.1% |
P
S
|
4,000,000 | $36,120,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALMS
ALUMIS INC
|
Healthcare | 1.64% | 0.59% |
#16
15
Prev: #31
|
3.7 | 1,488,200 | 69.3% |
P
S
|
3,635,596 | $35,483,417 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 1.63% | 1.48% |
#17
1
Prev: #18
|
1.2 | -105,000 | -8.6% |
P
S
|
1,120,000 | $35,324,800 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NAMS
NEWAMSTERDAM PH...
|
Healthcare | 1.62% | 4.27% |
#18
8
Prev: #10
|
0.6 | -1,175,000 | -54.0% |
P
S
|
1,000,000 | $35,080,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 1.53% | 3.22% |
#19
7
Prev: #12
|
0.6 | -600,000 | -31.2% |
P
S
|
1,325,000 | $33,138,250 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 1.39% | 2.35% |
#20
7
Prev: #13
|
0.6 | -280,200 | -20.6% |
P
S
|
1,083,000 | $30,053,250 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BIOA
BIOAGE LABS INC
|
Healthcare | 1.25% | 0.87% |
#21
6
Prev: #27
|
1.0 | -100,000 | -4.7% |
P
S
|
2,040,605 | $26,997,204 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 0.99% | — |
#22
Prev: #—
|
3.9 | 100,000 | no change |
NEW
|
100,000 | $21,324,000 | 2015 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 0.95% | 1.23% |
#23
2
Prev: #21
|
0.9 | -50,000 | -16.7% |
P
S
|
250,000 | $20,470,000 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRBP
CORBUS PHARMACE...
|
Healthcare | 0.88% | 2.07% |
#24
10
Prev: #14
|
0.9 | -30,029 | -1.3% |
P
S
|
2,344,971 | $19,088,064 | 2016 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GHRS
GH RESEARCH PLC
|
Healthcare | 0.76% | 1.89% |
#25
10
Prev: #15
|
0.3 | -616,439 | -32.2% |
P
S
|
1,300,000 | $16,510,000 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACLX
ARCELLX INC
|
Healthcare | 0.00% | 4.39% |
Sold All 😨
(Was: #8) |
0.0 | -775,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 0.00% | 1.74% |
Sold All 😨
(Was: #16) |
0.0 | -625,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KRRO
KORRO BIO INC
|
Healthcare | 0.00% | 1.54% |
Sold All 😨
(Was: #17) |
0.0 | -465,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MTSR
METSERA INC
|
Healthcare | 0.00% | 1.44% |
Sold All 😨
(Was: #19) |
0.0 | -400,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RNA
AVIDITY BIOSCIE...
|
Healthcare | 0.00% | 0.90% |
Sold All 😨
(Was: #26) |
0.0 | -300,000 | -100.0% |
CLOSED
|
— | $— | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMEA
BIOMEA FUSION I...
|
Healthcare | 0.00% | 0.50% |
Sold All 😨
(Was: #32) |
0.0 | -3,570,872 | -100.0% |
CLOSED
|
— | $— | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 0.00% | 0.28% |
Sold All 😨
(Was: #35) |
0.0 | -200,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 42 holdings